{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:34:12Z","timestamp":1792856052113,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09113-7","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:04:02Z","timestamp":1763539442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["CAR T Cell Therapy for Rheumatoid Arthritis"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5763-6582","authenticated-orcid":false,"given":"Michael","family":"Freeley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"12","key":"9113_CR1","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","volume":"55","author":"S Alivernini","year":"2022","unstructured":"Alivernini S, Firestein GS, McInnes IB (2022) The pathogenesis of rheumatoid arthritis. Immunity 55(12):2255\u20132270","journal-title":"Immunity"},{"issue":"10","key":"9113_CR2","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1093\/rheumatology\/keaa232","volume":"59","author":"LE Dedmon","year":"2020","unstructured":"Dedmon LE (2020) The genetics of rheumatoid arthritis. Rheumatology 59(10):2661\u20132670","journal-title":"Rheumatology"},{"issue":"1","key":"9113_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/art.21575","volume":"54","author":"L Klareskog","year":"2006","unstructured":"Klareskog L, Stolt P, Lundberg K, K\u00e4llberg H, Bengtsson C, Grunewald J et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA\u2013DR (shared epitope)\u2013restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54(1):38\u201346","journal-title":"Arthritis Rheum"},{"key":"9113_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.molimm.2025.06.008","volume":"184","author":"S Ganeshalingam","year":"2025","unstructured":"Ganeshalingam S, Wilson NJ, Ciciriello S, Antonipillai J, Achuthan AA (2025) Cellular interactions in maintaining an inflammatory microenvironment in rheumatoid arthritis. Mol Immunol 184:112\u2013122","journal-title":"Mol Immunol"},{"issue":"4","key":"9113_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/antib12040069","volume":"12","author":"M Paroli","year":"2023","unstructured":"Paroli M, Sirinian MI (2023) When autoantibodies are missing: the challenge of seronegative rheumatoid arthritis. Antibodies (Basel) 12(4):69","journal-title":"Antibodies (Basel)"},{"issue":"7","key":"9113_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St.Clair EW, Arayssi T, Carandang K et al (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 73(7):924\u2013939","journal-title":"Arthritis Care Res"},{"issue":"1","key":"9113_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9113_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS et al (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4(1):18001","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"9113_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0707-1","volume":"17","author":"G Nagy","year":"2015","unstructured":"Nagy G, Van Vollenhoven RF (2015) Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther 17(1):181","journal-title":"Arthritis Res Ther"},{"issue":"6382","key":"9113_CR10","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361\u20131365","journal-title":"Science"},{"issue":"22","key":"9113_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS (2024) CAR T cells and T-cell therapies for cancer: a translational science review. JAMA 332(22):1924","journal-title":"JAMA"},{"issue":"1","key":"9113_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, Von Bergwelt-Baildon M, Kobold S (2019) Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 120(1):26\u201337","journal-title":"Br J Cancer"},{"issue":"1","key":"9113_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(23)00631-9","volume":"25","author":"B Furlow","year":"2024","unstructured":"Furlow B (2024) FDA investigates risk of secondary lymphomas after CAR-T immunotherapy. Lancet Oncol 25(1):21","journal-title":"Lancet Oncol"},{"issue":"11","key":"9113_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN (2024) Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol 24(11):830\u2013845","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"9113_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, M\u00fcller F, Taubmann J, Mackensen A, Wang W, Furie RA et al (2024) Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol 20(9):531\u2013544","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"9113_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jtha.2024.09.024","volume":"23","author":"E Friedberg","year":"2025","unstructured":"Friedberg E, Wohlfarth P, Schiefer AI, Skrabs C, Pickl WF, Worel N et al (2025) Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost 23(1):262\u2013266","journal-title":"J Thromb Haemost"},{"issue":"11","key":"9113_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101794","volume":"5","author":"J Wickel","year":"2024","unstructured":"Wickel J, Schnetzke U, Sayer-Klink A, Rinke J, Borie D, Dudziak D et al (2024) Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome. Cell Rep Med 5(11):101794","journal-title":"Cell Rep Med"},{"issue":"8","key":"9113_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100676","volume":"6","author":"A Par\u00eds-Mu\u00f1oz","year":"2025","unstructured":"Par\u00eds-Mu\u00f1oz A, Alcobendas-Rueda RM, Verd\u00fa-S\u00e1nchez C, Udaondo C, Gal\u00e1n-G\u00f3mez V, Gonz\u00e1lez-Mart\u00ednez B et al (2025) CD19 CAR-T cell therapy in a pediatric patient with MDA5\u2009+\u2009dermatomyositis and rapidly progressive interstitial lung disease. Med 6(8):100676","journal-title":"Med"},{"issue":"2","key":"9113_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","volume":"48","author":"BV Kumar","year":"2018","unstructured":"Kumar BV, Connors TJ, Farber DL (2018) Human T cell development, localization, and function throughout life. Immunity 48(2):202\u2013213","journal-title":"Immunity"},{"issue":"4","key":"9113_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004727","volume":"10","author":"D Szabo","year":"2024","unstructured":"Szabo D, Balogh A, Gopcsa L, Giba-Kiss L, Lakatos G, Paksi M et al (2024) Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. RMD Open 10(4):e004727","journal-title":"RMD Open"},{"issue":"6","key":"9113_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20(6):359\u2013371","journal-title":"Nat Rev Clin Oncol"},{"key":"9113_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae714","author":"A Masihuddin","year":"2024","unstructured":"Masihuddin A, Liebowitz J, Reshef R, Bathon J (2024) Remission of lymphoma and rheumatoid arthritis following anti-CD19 chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keae714","journal-title":"Rheumatology"},{"issue":"11","key":"9113_CR23","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/ard-2024-226017","volume":"83","author":"A Haghikia","year":"2024","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, B\u00f6ttcher M, Pappa V, Motte J et al (2024) Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia Gravis. Ann Rheum Dis 83(11):1597\u20131598","journal-title":"Ann Rheum Dis"},{"key":"9113_CR24","doi-asserted-by":"crossref","unstructured":"Albach FN, Minopoulou I, Wilhelm A, Biesen R, Kleyer A, Wiebe E et al (2025) Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology. keaf077","DOI":"10.1093\/rheumatology\/keaf077"},{"issue":"7","key":"9113_CR25","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.ard.2025.03.018","volume":"84","author":"AC Pecher","year":"2025","unstructured":"Pecher AC, Hensen L, Schairer-Marquardt R, Kowarik M, Richter V, Bethge W et al (2025) Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation. Ann Rheum Dis 84(7):1284\u20131286","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"9113_CR26","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132","journal-title":"Nat Med"},{"issue":"2","key":"9113_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/ard-2024-226437","volume":"84","author":"M Lidar","year":"2025","unstructured":"Lidar M, Rimar D, David P, Jacoby E, Shapira-Frommer R, Itzhaki O et al (2025) CD-19 CAR-T cells for polyrefractory rheumatoid arthritis. Ann Rheum Dis 84(2):370\u2013372","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"9113_CR28","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","volume":"35","author":"Y Li","year":"2025","unstructured":"Li Y, Li S, Zhao X, Sheng J, Xue L, Schett G et al (2025) Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis. Cell Res 35(3):220\u2013223","journal-title":"Cell Res"},{"issue":"1","key":"9113_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH et al (2023) Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis Optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther 8(1):5","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"9113_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","volume":"80","author":"B Zhang","year":"2021","unstructured":"Zhang B, Wang Y, Yuan Y, Sun J, Liu L, Huang D et al (2021) In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells. Ann Rheum Dis 80(2):176\u2013184","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9113_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4049\/jimmunol.2100643","volume":"208","author":"KB Whittington","year":"2022","unstructured":"Whittington KB, Prislovsky A, Beaty J, Albritton L, Radic M, Rosloniec EF (2022) CD8\u2009+\u2009T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4\u2009+\u2009T cells in an antigen-specific manner and inhibit the development of autoimmune arthritis. J Immunol 208(1):16\u201326","journal-title":"J Immunol"},{"issue":"7","key":"9113_CR32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DAA Vignali","year":"2008","unstructured":"Vignali DAA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8(7):523\u2013532","journal-title":"Nat Rev Immunol"},{"key":"9113_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.846300","volume":"9","author":"CQ Chu","year":"2022","unstructured":"Chu CQ (2022) Highlights of strategies targeting fibroblasts for novel therapies for rheumatoid arthritis. Front Med 9:846300","journal-title":"Front Med"},{"key":"9113_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/ITT.S291767","volume":"10","author":"R Bughda","year":"2021","unstructured":"Bughda R, Dimou P, D\u2019Souza RR, Klampatsa A (2021) Fibroblast activation protein (FAP)-Targeted CAR-T cells: launching an attack on tumor stroma. ITT 10:313\u2013323","journal-title":"ITT"},{"issue":"7","key":"9113_CR35","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s13346-023-01308-9","volume":"13","author":"S Shahvali","year":"2023","unstructured":"Shahvali S, Rahiman N, Jaafari MR, Arabi L (2023) Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv Transl Res 13(7):2041\u20132056","journal-title":"Drug Deliv Transl Res"},{"issue":"7774","key":"9113_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L et al (2019) Targeting cardiac fibrosis with engineered T cells. Nature 573(7774):430\u2013433","journal-title":"Nature"},{"issue":"6576","key":"9113_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, M\u00e9ndez Fern\u00e1ndez PO, Shewale SV, Li L et al (2022) CAR T cells produced in vivo to treat cardiac injury. Science 375(6576):91\u201396","journal-title":"Science"},{"issue":"3","key":"9113_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/ard.2007.074229","volume":"67","author":"A Kavanaugh","year":"2008","unstructured":"Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K et al (2008) Assessment of rituximab\u2019s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 67(3):402\u2013408","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"9113_CR39","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/ard.2007.080960","volume":"67","author":"RM Thurlings","year":"2008","unstructured":"Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP (2008) Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 67(7):917\u2013925","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9113_CR40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur C, Eckstein M, Velden J, Rauber S, Bergmann C, Auth J et al (2025) CD19-CAR t-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis 84(1):106\u2013114","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"9113_CR41","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen M, M\u00fcller F, Wirsching A, Kharboutli S, Spoerl S, D\u00fcsing C et al (2025) Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol 7(6):e424\u2013e433","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"9113_CR42","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1093\/rheumatology\/keae046","volume":"63","author":"JA G\u00f3mez-Puerta","year":"2024","unstructured":"G\u00f3mez-Puerta JA, Ponce A, Triguero A, Fern\u00e1ndez de Larrea C, Sanmart\u00ed R (2024) Transient palindromic rheumatism induced by chimeric antigen receptor T-cell therapy. Rheumatology (Oxford) 63(8):e215\u2013e216","journal-title":"Rheumatology (Oxford)"},{"key":"9113_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152610","volume":"71","author":"JA G\u00f3mez-Puerta","year":"2025","unstructured":"G\u00f3mez-Puerta JA, Monegal A, Ponce A, Peris P, Mart\u00ednez-Cibrian N, Sarmiento-Monroy JC et al (2025) Rheumatologic complications of CAR-T cell therapy. Experience of a single center. Semin Arthritis Rheum 71:152610","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"9113_CR44","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","volume":"31","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Wirsching A, Hagen M, V\u00f6lkl S, Tur C, Raimondo MG et al (2025) BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat Med 31(6):1793\u20131797","journal-title":"Nat Med"},{"key":"9113_CR45","unstructured":"Chahin N, Sahagian G, Feinberg MH, Stewart CA, Jewell CM, Kurtoglu M et al (2025) Durability of response to B-Cell maturation Antigen-Directed mRNA cell therapy in myasthenia Gravis. Ann Clin Transl Neurol"},{"issue":"22","key":"9113_CR46","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1056\/NEJMc2502297","volume":"392","author":"L Zhang","year":"2025","unstructured":"Zhang L, Gao Z, Pan H, Li R, Fang L, Li W et al (2025) BCMA-targeted T-cell engager for autoimmune hemolytic anemia after CD19 CAR T-cell therapy. N Engl J Med 392(22):2282\u20132284","journal-title":"N Engl J Med"},{"issue":"2","key":"9113_CR47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ et al (2024) Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med 30(2):338\u2013341","journal-title":"Nat Med"},{"issue":"6753","key":"9113_CR48","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A et al (2025) In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388(6753):1311\u20131317","journal-title":"Science"},{"issue":"12","key":"9113_CR49","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41422-022-00745-4","volume":"32","author":"S Castelli","year":"2022","unstructured":"Castelli S, Young RM, June CH (2022) Off-the-shelf CAR T cells to treat cancer. Cell Res 32(12):1036\u20131037","journal-title":"Cell Res"},{"issue":"6726","key":"9113_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4793","volume":"386","author":"NR Reddy","year":"2024","unstructured":"Reddy NR, Maachi H, Xiao Y, Simic MS, Yu W, Tonai Y et al (2024) Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs. Science 386(6726):eadl4793","journal-title":"Science"},{"issue":"11","key":"9113_CR51","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1038\/s41591-023-02613-z","volume":"29","author":"OV Britanova","year":"2023","unstructured":"Britanova OV, Lupyr KR, Staroverov DB, Shagina IA, Aleksandrov AA, Ustyugov YY et al (2023) Targeted depletion of TRBV9\u2009+\u2009T cells as immunotherapy in a patient with ankylosing spondylitis. Nat Med 29(11):2731\u20132736","journal-title":"Nat Med"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09113-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09113-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09113-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:03:30Z","timestamp":1763543010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09113-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9113"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09113-7","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}